234 related articles for article (PubMed ID: 27228285)
1. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miR-148a-3p and miR-106a-5p as Biomarkers for Prostate Cancer: Pilot Study.
Coman RA; Schitcu VH; Budisan L; Raduly L; Braicu C; Petrut B; Coman I; Berindan-Neagoe I; Al Hajjar N
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790213
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
7. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
9. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
10. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
11. A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
Chen ZH; Zhang GL; Li HR; Luo JD; Li ZX; Chen GM; Yang J
Prostate; 2012 Sep; 72(13):1443-52. PubMed ID: 22298030
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer.
Gao Y; Guo Y; Wang Z; Dai Z; Xu Y; Zhang W; Liu Z; Li S
Neoplasma; 2016; 63(4):623-8. PubMed ID: 27268927
[TBL] [Abstract][Full Text] [Related]
13. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
15. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
16. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
17. Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value.
Cai B; Peng JH
Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414754
[TBL] [Abstract][Full Text] [Related]
18. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
[TBL] [Abstract][Full Text] [Related]
19. miRNAs as novel biomarkers in the management of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2017 May; 55(5):715-736. PubMed ID: 26751899
[TBL] [Abstract][Full Text] [Related]
20. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]